On this page
TGFBR1
transforming growth factor beta receptor 1
The *TGFBR1* gene provides instructions for making a protein that plays a crucial role in cell signalling, influencing processes like cell growth, division, and maturation. The *TGFBR1* gene is vital for producing the transforming growth factor-beta (TGF-β) receptor type 1, a protein integral to cellular communication.
TGFBR1 is located on the long (q) arm of chromosome 9, at band 9q22.33. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 9 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The *TGFBR1* gene, also known as transforming growth factor beta receptor 1, encodes a protein that acts as a receptor for the transforming growth factor-beta (TGF-β) pathway. This pathway is a critical signalling cascade that controls numerous cellular functions, including cell proliferation, differentiation, movement, and programmed cell death.
Dysregulation of the TGF-β pathway, often due to pathogenic variants in genes like *TGFBR1*, can lead to various health conditions. Understanding the role of *TGFBR1* is important for comprehending the mechanisms behind these conditions and for informing potential therapeutic strategies.
What the gene does
The protein encoded by the *TGFBR1* gene, transforming growth factor-beta (TGF-β) receptor type 1, is a transmembrane protein. This means it spans the cell membrane, allowing it to receive signals from the extracellular environment and relay them into the cell's interior. Its primary function is signal transduction, converting external cues into intracellular responses.
Upon binding of TGF-β ligands to the extracellular portion of the receptor, TGFBR1 becomes activated. This activation typically involves its interaction with another cell surface receptor, forming a complex that initiates the downstream signalling cascade known as the TGF-β pathway. This pathway is instrumental in regulating cellular activities such as stimulating cell growth and division, promoting cell maturation into specialised types, facilitating cell movement, and orchestrating controlled cell death (apoptosis).
Because the TGF-β receptor type 1 helps prevent uncontrolled or excessively rapid cell growth and division, it is considered a tumour suppressor. Its proper functioning is essential for maintaining cellular homeostasis and preventing disease.
Video: Genetics 101
Chromosome location
The *TGFBR1* gene is situated on chromosome 9, specifically at location 9q22.33. Chromosomes are highly organised structures found within cells, carrying genetic information. The 'q' indicates the long arm of the chromosome, '22' refers to the region, and '33' denotes the band within that region. This precise genomic address helps in mapping and understanding the gene's position within the human genome.
Protein structure
The TGFBR1 protein is composed of 503 amino acids. It features several key domains crucial for its function. The GS domain, spanning amino acids 175-204, is involved in signal transduction. A specific FKBP1A-binding motif, located at amino acids 193-194, facilitates interactions with other proteins. The extensive Protein kinase domain, from amino acids 205-495, is responsible for the protein's enzymatic activity, enabling it to phosphorylate other proteins and propagate signalling cascades.
Key variants
Variants within the *TGFBR1* gene can alter the protein's structure and function, leading to disruptions in the TGF-β signalling pathway. These changes can range from small single nucleotide polymorphisms (SNPs) to larger deletions or insertions. Pathogenic variants can impair the receptor's ability to bind to its ligand, transmit signals effectively, or interact with other proteins in the pathway.
The clinical consequences of such variants depend on the specific alteration and its impact on protein function, potentially resulting in a spectrum of associated conditions.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1126A>G | p.Lys376Glu | Pathogenic | ★★☆☆ | Familial thoracic aortic aneurysm and aortic dissection |
c.1457T>C | p.Leu486Ser | Pathogenic/Likely pathogenic | ★★☆☆ | TGFBR1-related disorder |
c.1459C>T | p.Arg487Trp | Pathogenic/Likely pathogenic | ★★☆☆ | Loeys-Dietz syndrome 1 |
c.1460G>A | p.Arg487Gln | Pathogenic | ★★☆☆ | Loeys-Dietz syndrome 1 |
c.238C>T | p.Arg80Ter | Pathogenic/Likely pathogenic | ★★☆☆ | TGFBR1-related disorder |
c.640G>A | p.Gly214Ser | Pathogenic/Likely pathogenic | ★★☆☆ | Loeys-Dietz syndrome 1 |
c.679G>A | p.Glu227Lys | Pathogenic/Likely pathogenic | ★★☆☆ | Familial thoracic aortic aneurysm and aortic dissection |
c.680AAG[1] | p.Glu228del | Pathogenic | ★★☆☆ | Loeys-Dietz syndrome |
c.700T>C | p.Phe234Leu | Pathogenic/Likely pathogenic | ★★☆☆ | TGFBR1-related disorder |
c.722C>T | p.Ser241Leu | Pathogenic/Likely pathogenic | ★★☆☆ | Loeys-Dietz syndrome 1 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the *TGFBR1* gene are primarily associated with connective tissue disorders and an increased risk of certain cancers. One notable condition is Loeys-Dietz syndrome, an autosomal dominant disorder affecting connective tissue throughout the body, often presenting with arterial aneurysms and skeletal abnormalities. Additionally, *TGFBR1* variants have been linked to an increased risk of familial thoracic aortic aneurysm and dissection, prostate cancer, and certain forms of skin cancer, including multiple self-healing squamous epithelioma.
Inheritance pattern
Conditions caused by pathogenic TGFBR1 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
In the United Kingdom, the *TGFBR1* gene is recognised on several NHS Genomic Medicine Service (GMS) approved panels, indicating its clinical significance in diagnostic testing. It is featured on panels for conditions such as Arthrogryposis (R83), Clefting, COVID-19 research, DDG2P, Ehlers Danlos syndrome with a likely monogenic cause (R101), Foetal anomalies (R21), Infantile enterocolitis & monogenic inflammatory bowel disease, Familial Pneumothorax (R190), Primary immunodeficiency or monogenic inflammatory bowel disease (R15), Rare syndromic craniosynostosis or isolated multisuture synostosis (R100), and Thoracic aortic aneurysm or dissection (R125).
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Research into the effects of lifestyle on individuals with *TGFBR1* variants is ongoing. Generally, maintaining a heart-healthy lifestyle, including a balanced diet rich in fruits, vegetables, and whole grains, and engaging in regular, moderate physical activity, is recommended for overall well-being. For individuals with connective tissue disorders, avoiding activities that place excessive strain on the cardiovascular system or joints may be advised. Smoking cessation is universally recommended due to its detrimental effects on cardiovascular health, which is particularly relevant given the association of *TGFBR1* with aortic conditions. However, there is no conclusive evidence that specific lifestyle interventions can prevent the onset or progression of conditions directly linked to *TGFBR1* variants.
Supplement considerations
There is currently no conclusive scientific evidence to suggest that specific dietary supplements can prevent, treat, or mitigate the effects of conditions caused by *TGFBR1* variants. Any individual considering taking supplements should first discuss this with a healthcare professional. It is important to remember that supplements can interact with medications and may not be suitable for everyone.
Frequently asked questions
What is the primary function of the *TGFBR1* gene?
The *TGFBR1* gene provides instructions for the transforming growth factor-beta (TGF-β) receptor type 1 protein, which is crucial for cell signalling. It transmits signals from outside the cell to regulate processes like cell growth, division, and differentiation.
What is Loeys-Dietz syndrome, and how is it related to *TGFBR1*?
Loeys-Dietz syndrome is an autosomal dominant connective tissue disorder. Pathogenic variants in the *TGFBR1* gene are a known cause of this syndrome, leading to abnormalities in blood vessels and skeletal structures.
Are *TGFBR1* variants associated with cancer risk?
Yes, variants in the *TGFBR1* gene have been linked to an increased risk of certain cancers, including prostate cancer and a form of skin cancer known as multiple self-healing squamous epithelioma.
Is *TGFBR1* included in routine genetic testing in the UK?
The *TGFBR1* gene is included on several NHS Genomic Medicine Service (GMS) approved panels in the UK, indicating its relevance for diagnostic testing in specific conditions such as connective tissue disorders and aortic conditions.
Can lifestyle changes prevent conditions associated with *TGFBR1* variants?
While a generally healthy lifestyle is beneficial for overall well-being, there is no definitive evidence that specific lifestyle changes can prevent the onset or progression of conditions directly caused by *TGFBR1* variants. Consult a healthcare professional for personalised advice.
References
- Pezzini A, Del Zotto E, Giossi A. Transforming growth factor β signaling perturbation in the Loeys-Dietz syndrome. Current medicinal chemistry. 2012. PMID: 22335518
- Cardoso S, Robertson SP, Daniel PB. TGFBR1 mutations associated with Loeys-Dietz syndrome are inactivating. Journal of receptor and signal transduction research. 2012. PMID: 22414221
- Goudie DR, D'Alessandro M, Merriman B. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nature genetics. 2011. PMID: 21358634
- Van Hemelrijk C, Renard M, Loeys B. The Loeys-Dietz syndrome: an update for the clinician. Current opinion in cardiology. 2010. PMID: 20838339
- Loeys BL, Schwarze U, Holm T. Aneurysm syndromes caused by mutations in the TGF-beta receptor. The New England journal of medicine. 2006. PMID: 16928994